Novo Nordisk A/S (NYSE:NVO) Shares Sold by IHT Wealth Management LLC

IHT Wealth Management LLC trimmed its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 36.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,192 shares of the company's stock after selling 4,119 shares during the quarter. IHT Wealth Management LLC's holdings in Novo Nordisk A/S were worth $619,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Center for Financial Planning Inc. increased its holdings in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the period. Strategic Investment Solutions Inc. IL increased its holdings in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares during the period. Transce3nd LLC purchased a new position in Novo Nordisk A/S during the 4th quarter worth $33,000. Kelly Lawrence W & Associates Inc. CA purchased a new position in Novo Nordisk A/S during the 4th quarter worth $39,000. Finally, Albion Financial Group UT boosted its position in Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after acquiring an additional 278 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

NVO has been the subject of a number of analyst reports. BNP Paribas assumed coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an "underperform" rating for the company. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. BMO Capital Markets reissued a "market perform" rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of "Hold" and an average target price of $135.00.

Novo Nordisk A/S Trading Up 1.4 %

Shares of NYSE:NVO traded up $0.90 during mid-day trading on Wednesday, reaching $66.06. 4,544,967 shares of the company were exchanged, compared to its average volume of 6,140,560. The firm has a market cap of $296.45 billion, a price-to-earnings ratio of 20.10, a P/E/G ratio of 0.90 and a beta of 0.61. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The firm's 50-day simple moving average is $72.84 and its 200 day simple moving average is $88.85.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were paid a dividend of $0.7874 per share. This represents a dividend yield of 1.2%. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S's dividend payout ratio is 49.54%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.